Vol. 6 No. 11 (2026): November
Reimbursement Reviews

Glecaprevir-Pibrentasvir (Maviret)

decorative image of the issue cover

Published November 4, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Glecaprevir-pibrentasvir (Maviret) tablet (100 mg glecaprevir / 40 mg pibrentasvir) or granules (50 mg glecaprevir / 20 mg pibrentasvir) per sachet taken orally.
  • Indication: For the treatment of acute and chronic HCV infection in adults and pediatric patients 3 years of age and older and weighing ≥ 12 kg.